TRGNY

Transgene . (TRGNY)

Transgene S.A. ADS (MM)

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:TRGNY

일자	시간	출처	헤드라인	심볼	기업
2005/10/19	15:00	PR Newswire (US)	Transgene : Cash Position and Net Cash Expenditures as of September 30, 2005	NASDAQ:TRGNY
2005/09/21	14:01	PR Newswire (US)	Transgene to Voluntarily Delist From Nasdaq	NASDAQ:TRGNY
2005/08/03	14:01	PR Newswire (US)	Transgene Announces First Half 2005 Financial Results	NASDAQ:TRGNY
2005/07/21	14:01	PR Newswire (US)	Transgene Announces Achievement of Clinical Milestone by Merck & Co., Inc. Using Transgene's Proprietary Technology	NASDAQ:TRGNY
2005/07/12	02:01	PR Newswire (US)	Transgene Raises Euro 34.9 Million	NASDAQ:TRGNY
2005/05/20	14:01	PR Newswire (US)	Transgene Announces 20-F Form Filing	NASDAQ:TRGNY
2005/05/17	14:01	PR Newswire (US)	Transgene's Therapeutic Vaccine MVA-MUC1-IL2 at ASCO:	NASDAQ:TRGNY
2005/05/16	14:01	PR Newswire (US)	Transgene Presents Updated Positive Phase II Data of Its Therapeutic Vaccine MVA-MUC1-IL2 In Prostate Cancer at Annual ASCO Meet	NASDAQ:TRGNY
2005/04/26	14:01	PR Newswire (US)	Transgene to Present at the 2nd Rodman & Renshaw Annual Global Healthcare Conference	NASDAQ:TRGNY
2005/04/13	14:01	PR Newswire (US)	Transgene: Cash Position and Net Cash Expenditures as of March 31, 2005	NASDAQ:TRGNY
2005/04/05	14:01	PR Newswire (US)	Transgene to Present Phase II Data of Its MVA-UC1-IL2 Cancer Vaccine at ASCO's 2005 Annual Meeting	NASDAQ:TRGNY
2005/02/23	15:00	PR Newswire (US)	Transgene Announces Fiscal Year 2004 Financial Results	NASDAQ:TRGNY
2005/02/23	15:00	PR Newswire (US)	Transgene: New Strategy in Therapeutic Vaccines, MVA-Muc1-IL2 Meets Primary Endpoint in Lung Cancer Phase II	NASDAQ:TRGNY
2005/02/15	14:01	PR Newswire (US)	Transgene Appoints Jean-Yves Bonnefoy as New Chief Scientific Officer	NASDAQ:TRGNY
2004/12/08	14:01	PR Newswire (US)	Transgene Appoints Philippe Archinard As New Chief Executive Officer	NASDAQ:TRGNY
2004/12/01	01:34	PR Newswire (US)	Transgene Moves Forward Its Vaccine Candidate MVA-HPV-IL2 In A Novel Approach Against Pre-Cancerous Cervical Lesions	NASDAQ:TRGNY
2004/11/03	14:01	PR Newswire (US)	Transgene: Cash Position and Net Cash Expenditures as of September 30, 2004	NASDAQ:TRGNY
2004/08/04	14:01	PR Newswire (US)	Transgene Announces Second Quarter and First Half 2004 Financial Results	NASDAQ:TRGNY
2004/07/01	22:31	PR Newswire (US)	Transgene Manufactures Clinical Lots of HIV Vaccine Candidates for the EUROVAC Project	NASDAQ:TRGNY
2004/06/15	15:00	PR Newswire (US)	Merial and Transgene Sign a Collaboration Agreement to Develop Products for Animal Health	NASDAQ:TRGNY	Transgene S.A. ADS (MM)
2004/06/15	14:01	PR Newswire (US)	Merial and Transgene Sign a Collaboration Agreement to Develop Products for Animal Health	NASDAQ:TRGNY
2004/06/08	14:01	PR Newswire (US)	Transgene Presents Data on MVA-MUC1-IL2 Cancer Vaccine at ASCO and ASGT Annual Meetings	NASDAQ:TRGNY
2004/05/12	22:45	PR Newswire (US)	Transgene to Present Data at 2004 ASCO Annual Meeting	NASDAQ:TRGNY
2004/05/05	14:01	PR Newswire (US)	Transgene Announces First Quarter 2004 Financial Results	NASDAQ:TRGNY
2004/04/14	14:01	PR Newswire (US)	Transgene: Data Presented at The American Association of Cancer Research Annual Meeting Suggest Significant Opportunities for An	NASDAQ:TRGNY
2004/03/18	14:01	PR Newswire (US)	Transgene's MVA-HPV-IL2 Vaccine Shows Activity in Phase II Clinical Trial	NASDAQ:TRGNY
2004/02/11	14:01	PR Newswire (US)	Transgene Announces Fourth Quarter and Fiscal Year 2003 Financial Results	NASDAQ:TRGNY
2004/02/09	14:00	PR Newswire (US)	Transgene Reports Positive Interim Phase II Data from MVA-Muc1-IL2 Cancer Vaccine Program	NASDAQ:TRGNY
2003/11/05	14:01	PR Newswire (US)	Transgene Announces Third Quarter 2003 Financial Results	NASDAQ:TRGNY
2003/11/03	14:01	PR Newswire (US)	Transgene Signs Pre-Clinical AIDS Vaccine Manufacturing Agreement With ANRS and INSERM	NASDAQ:TRGNY